Lates News

Biotechnology company Avidity Biosciences rose 6.7% in early trading, after the company announced the pricing of a $600 million stock offering to advance its clinical projects and expand its commercial infrastructure. The funds raised will be used to support the development of its AOC platform and potential product launches, laying the foundation for the company's future growth.